Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
2006; National Institutes of Health; Volume: 91; Issue: 5 Linguagem: Inglês
Autores
Pilar Giraldo, Paz Latre, Pilar Alfonso, Antonio Acedo, Dora Alonso, Abelardo Bárez, Alejandro Corrales, Rafael Franco, Vanessa Roldán, Sol Serrano, Miguel Pocovı́,
Tópico(s)Carbohydrate Chemistry and Synthesis
ResumoIn a prospective, open-label study, 25 patients with mild-to-moderate type 1 Gaucher's disease (GD1) were treated with miglustat (Zavesca), an oral glucosylceramide synthase inhibitor, over 12 months. Of the 25 patients, 10 were therapy-naïve and 15 had previously received enzyme replacement therapy (ERT). Clinical status, blood parameters, biomarkers, and organomegaly were assessed at baseline at 6 months and at 12 months. At 6 months the previously untreated patients showed a mean increase in hemoglobin of 0.77 g/dL, platelet counts improved or remaining stable, chitotriosidase and CCL18 decreased. These results were similar to those observed in 40 Spanish GD1 patients on ERT. Bone marrow infiltration cleared at 12 months. In the previously treated group, clinical and hematologic parameters and biomarkers were maintained/ improved at 12 months. Miglustat was well tolerated. The efficacy of miglustat treatment after 6 months was comparable to that of ERT.
Referência(s)